We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ADVISORY COMMITTEES SAY 'NO' TO PSORIASIS DRUG
ADVISORY COMMITTEES SAY 'NO' TO PSORIASIS DRUG
July 16, 2004
A joint FDA advisory committee said it could not approve Allergan’s oral retinoid treatment for psoriasis because even though the treatment demonstrated modest efficacy in pivotal trials, the accompanying risk management program is inadequate.